Emerging Companies

Ron Cohen MD, President and Chief Executive Officer, Acorda Therapeutics, Inc., discusses what is necessary to create an environment of biotech innovation.

BIO featured Jan Lundberg of Eli Lilly as this year's fireside chat speaker at the BIO Investor Forum!

Stephan Tanda, Managing Board Member with Royal DSM, discusses what is necessary to create an environment of biotech innovation.

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act. BIOtechNOW’s JOBS Act Deconstructed series explores why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage.

The Jumpstart Our Business Startups (JOBS) Act was signed into law by President Obama on April 5, 2012. The law mandated certain changes to Rule 506 of SEC Regulation D designed to spur capital formation for growing innovators. The required Regulation D reforms took effect on September 23, 2013, after being finalized by the SEC this summer. A summary of these changes is outlined below.

Since the 2012 signing of the Jumpstart Our Business Startups Act (JOBS Act), many small businesses in the biotech community have benefited from the JOBS Act by being able to focus on research and development rather than onerous and burdensome regulations.

The fifth annual edition of Scientific American Worldview explores ongoing challenges and opportunities in the biopharmaceutical industry, including the looming potential of an “innovation cliff.”

Rob Wright, chief editor of Life Science Leader, previews the “What Does Diversity Mean in the 21st Century?” panel he will be moderating at the Diversity, Inclusion, and Life Sciences Symposium Monday, April 22 in Chicago, Ill.

Recently BIO hosted the 15th annual BIO CEO & Investor Conference at the Waldorf Astoria in New York City. The conference is the largest investor conference focused on for established and emerging publicly traded and select private biotech companies.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life sciences specialist in investment banking, and the most prolific.

The biosimilars pathway is critical for China's biotechnology industry – and this is evident in the investment the government is making in the manufacture of biotech products

Letters, Testimony & Comments

April 30 2015
On behalf of the Biotechnology Industry Organization Before the United States House of Representatives Committee on Financial Services, Subcommittee on Capital Markets and Government Sponsored Enterprises --- Legislative Proposals to Enhance Capital Formation and Reduce Regulatory Burdens
April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.

Press Releases

April 29 2016
Bill would enhance the voice of emerging companies at the SEC Washington, D.C. (April 29, 2016) – Today, the Biotechnology Innovation Organization (BIO) applauds Senators Heidi Heitkamp (D-ND), Dean Heller (R-NV) and Gary Peters (D-MI) for introducing the SEC Small Business Advocate Act, which would ensure that growing companies have a strong, independent voice at the Securities and Exchange Commission (SEC). 
February 9 2016
Elements of the President’s budget proposal for 2017 directly threaten his Administration’s goal of curing cancer through advances in precision medicine
February 2 2016
BIO applauds the House of Representatives for approving the SEC Small Business Advocate Act (H.R. 3784) and the Small Business Capital Formation Enhancement Act (H.R. 4168). These bills would enhance the role that small businesses play in the decision-making process at the Securities and Exchange Commission, ensuring that SEC policies support the growth of emerging biotech innovators.
December 16 2015
BIO today welcomed legislation to extend critical tax incentives that are important to biotechnology companies. The legislation would make permanent the important Research & Development Tax Credit.
December 2 2015
BIO supports legislation to follow up on the success of the JOBS Act